|
|
Post by peppy on Nov 9, 2016 19:30:41 GMT -5
Not sure would ask this. 97 million shares short per the NASDAQ site. How do you think this will play out tomorrow? if we open above or trade above 70 cents, price should go to a dollar. the January low was 64 cents. Good job with face book patten!
|
|
|
|
Post by patten1962 on Nov 9, 2016 19:34:13 GMT -5
Up a bit. Lots of shorts are hanging on until 2017 for tax purposes. They probably have been shorting from $5+ and were waiting for bankrupcy or a better tax treatment. Not all 97MM are going to try to cover, this is not going to cause a short squeeze. Ty. Only question is, if you short at $5, why not cover at 47c? |
|
|
|
Post by traderdennis on Nov 9, 2016 19:56:59 GMT -5
Up a bit. Lots of shorts are hanging on until 2017 for tax purposes. They probably have been shorting from $5+ and were waiting for bankrupcy or a better tax treatment. Not all 97MM are going to try to cover, this is not going to cause a short squeeze. Ty. Only question is, if you short at $5, why not cover at 47c? Why pay taxes in April 2017 when you can defer to Apr 2018. Also it may make the difference between a short term and long term capital gain. |
|
|
|
Post by falconquest on Nov 9, 2016 19:58:17 GMT -5
My take away is that Matt and team have been busy. They have positioned themselves for success from each of the management team's respective areas of expertise but they still need to go sell Afrezza. While I come away mildly optimistic I think there remains a buying opportunity to occur late second or third quarter next year prior to several announced milestones occurring in Q4 2017. By the way, did Matt say they continue to have sex.....er, success at roughly 44:00? Lol!
|
|
|
|
Post by mnkdorbust on Nov 9, 2016 20:05:29 GMT -5
My take away is that Matt and team have been busy. They have positioned themselves for success from each of the management team's respective areas of expertise but they still need to go sell Afrezza. While I come away mildly optimistic I think there remains a buying opportunity to occur late second or third quarter next year prior to several announced milestones occurring in Q4 2017. By the way, did Matt say they continue to have sex.....er, success at roughly 44:00? Lol! He did. Maybe they are also working on inhaled viagra and he let it slip  |
|
|
|
Post by peppy on Nov 9, 2016 20:09:11 GMT -5
Up a bit. Lots of shorts are hanging on until 2017 for tax purposes. They probably have been shorting from $5+ and were waiting for bankrupcy or a better tax treatment. Not all 97MM are going to try to cover, this is not going to cause a short squeeze. Ty. Only question is, if you short at $5, why not cover at 47c? They, the shorts thought it was over. They will cover now.
|
|
|
|
Post by ilovekauai on Nov 9, 2016 20:18:20 GMT -5
Been gone all day. Just got home to all this great news from the CC. Congrats to Matt P & team! What a fighter this little company is. Bravo!
|
|
|
|
Post by dictatorsaurus on Nov 9, 2016 20:19:12 GMT -5
Great job with the cash but I'm still very worried about sales. I really don't feel they have figured out a way to successfully increase scripts yet.
|
|
|
|
Post by peppy on Nov 9, 2016 20:26:45 GMT -5
|
|
|
|
Post by tarheelblue004 on Nov 9, 2016 20:28:21 GMT -5
There will definitely be some short covering. MNKD just de-risked in a HUGE way, taking bankruptcy off the table for almost a year. Additionally, the balance sheet change as a result of the Sanofi payments and debt forgiveness, along with the Amphistar debt forgiveness, is massive. The value of this company in analyst models just significantly improved. There will be buyers and few sellers as a result of the value improvement and de-risking, and shorts who don't see any way this goes lower but can see it going higher would have to buy to close. So I agree peppy, I would be surprised to not see a large increase in SP and short covering. I've long been bullish MNKD, but for the first time they've cleaned up their balance sheet in the kind of way that clearly impacts Wall Street valuations. The two cents of an unbelievably thrilled MNKD long. GLTA. *edited to remove section on the profitability of shorting |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 9, 2016 20:50:40 GMT -5
Up a bit. Lots of shorts are hanging on until 2017 for tax purposes. They probably have been shorting from $5+ and were waiting for bankrupcy or a better tax treatment. Not all 97MM are going to try to cover, this is not going to cause a short squeeze. If you look at the short data I dont think its unreasonable to say 15-20 million shares have been shorted between here and 1.30. Not all of those 97 million are from 5+. I am sure there is plenty in there that have potential to lose gains. You are also assuming that Afrezza will still fail. Its failing now miserable but an SNY settlement should cause anyone short to come up with a strategy because what happens if MNKD makes it successful? Smart $$$ is not going to assume they are going to go bankrupt in 2017. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 9, 2016 20:58:21 GMT -5
Ty. Only question is, if you short at $5, why not cover at 47c? Why pay taxes in April 2017 when you can defer to Apr 2018. Also it may make the difference between a short term and long term capital gain. If the return is that great and it is now at risk do you think they really care? This isnt an etf. They are short a bio tech with massive gains. IMO they might not have cared earlier today but they def care now. |
|
|
|
Post by boomboom on Nov 9, 2016 21:24:51 GMT -5
Great job with the cash but I'm still very worried about sales. I really don't feel they have figured out a way to successfully increase scripts yet. You are correct, they have not. But what you should be proud of is that they are performing a lot of due diligence to understand their obstacles. It is almost incredible how patient Mike sounded with regards to the "42 reps", "understanding promotional sensitivity", and not burning cash before grasping Afrezzas best marketing strategy. They are clearly on a different agenda and timeline than us investors and it is a big learning lesson for me as someone sitting on the sidelines. I hope to take this type of experience with me to further my career in the corporate world. Its not about the pressure that is put on you but making the right decisions to do whats best in the allotted time you have. They had an allotted time of Q1 2017 and they outperformed, in my opinion, to allow proper runway to keep understanding how to best get their product in the hands of those who need and want it. They solved and are continuing to solve so many issues in parallel its a bit surreal and its a reflection of how hard they must be working. I really appreciate the approach Mike takes with the data available to them. It sounds like they are squeezing the fruit dry for data that will allow them to better understand how to optimize Afrezza marketing. Though I do not necessarily agree with all of it, it provides perspective when you hear things like the amount of reps was almost half of what we all expected to be out there (42 compared to 70). |
|
|
|
Post by dreamboatcruise on Nov 9, 2016 21:29:40 GMT -5
Great job with the cash but I'm still very worried about sales. I really don't feel they have figured out a way to successfully increase scripts yet. Get expanded payer coverage, remove or at least assist with paperwork for PA and support patients going on Afrezza so they have success that will be seen by docs... then start serious marketing to consumers. What they've laid out makes sense to me. It doesn't seem like something that will occur overnight, granted. |
|
|
|
Post by letitride on Nov 9, 2016 21:30:57 GMT -5
In my opinion the covering has already begun we didn't head for 13 mill shares today on speculative long accumulation alone based on this mornings financials. But given the tenacity of the shorts to date I don't expect them to go away until Afrezza is showing clear market acceptance. Hopefully I'm wrong because I wont miss them if they cut out in the morning.
|
|
